The Critical Role of Astragalus Polysaccharides for the Improvement of PPRAα-Mediated Lipotoxicity in Diabetic Cardiomyopathy

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Chen, Wei ^a   Xia, Yanping ^a   Zhao, Xuelan ^a   Wang, Hao ^a   Chen, Wenjie ^a   Yu, Maohua ^a   Li, Yiming ^a   Ye, Hongying ^a   Zhang, Yu ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ASTRAGALUS POLYSACCHARIDE; FATTY ACID; GLUCOSE; MYOSIN HEAVY CHAIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLANT MEDICINAL PRODUCT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; ENERGY METABOLISM; ENZYME INHIBITION; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; GENE ACTIVATION; GENE REPRESSION; GLUCOSE UTILIZATION; HEART DISEASE; LIPOTOXICITY; MALE; MOUSE; NONHUMAN;

ANIMALS; ASTRAGALUS MEMBRANACEUS; BLOOD GLUCOSE; BLOTTING, WESTERN; COLORIMETRY; DIABETIC CARDIOMYOPATHIES; ECHOCARDIOGRAPHY; FATTY ACIDS, NONESTERIFIED; INSULIN; MALE; MASS SPECTROMETRY; MICE; MICE, OBESE; MICE, TRANSGENIC; MUSCLE CELLS; MYOSIN HEAVY CHAINS; PHYTOTHERAPY; POLYSACCHARIDES; PPAR ALPHA; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRIGLYCERIDES;

MUS;

EID: 84866978494     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045541     Document Type: Article

References (28)

1. Rogger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, et al. (2011) Heart disease and stroke statistics-2011 update: a report from the Ametican Heart Association. Circulation 123(4): e18-e209.
2. Witteles RM, Fowler MB, (2008) Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 51(2): 93-102.
3. Battiprolu PK, Gillette TG, Wang ZV, Lavandero S, Hill JA, (2010) Diabetic cardiomyopathy: mechanisms and therapeutic targets. Drug Discov Today Dis Mech 7(2): e135-e143.
4. Carley AN, Severson DL, (2005) Fatty acid metabolsim is enhanced in type 2 diabetic hearts. Biochim Biophys Acta 1734: 112-126.
5. Lopaschuk GD, (2002) Metabolic abnormalities in the diabetic heart. Heart Fail Rev 7: 149-159.
6. Taegtmeyer H, McNulty P, Young ME, (2002) Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. Circulation 105: 1727-1733.
7. Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, et al. (2005) Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Edocrinology 146: 5341-5349.
8. Semeniuk LM, Kryski AJ, Severson DL, (2002) Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice. Am J Physiol Heart Circ Physiol 283: H976-H982.
9. Belke DD, Larsen TS, Gibbs EM, Severson DL, (2000) Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab 279: E1104-E1113.
10. Stanley WC, Chandler MP, (2002) Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail Rev 7: 115-130.
11. Thrainsdottir IS, von Bibra H, Malmberg K, Ryden L, (2004) Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure. J Cardiovasc Pharmacol 44: 101-108.
12. Rogers JH, Tamirisa P, Kovacs A, Weinheimer C, Courtois M, et al. (1999) RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. J Clin Invest 104: 567-576.
13. Chen W, Yu M, Li Y, (2008) Astragalus Polysaccharides: An Effective Treatment for Diabetes Prevention in NOD Mice. Exp Clin Endocrinol Diabetes 116(8): 468-474.
14. Chen W, Yu M, Li Y, (2010) Astragalus polysaccharides inhibited diabetic cardiomyopathy in hamsters depending on supression of heart chymase activation. J Diabetes Complica. 24(3): 199-208.
15. Chen W, Yu M, Li Y, Chen WJ, Xia Y, (2010) Beneficial effects of astragalus polysaccharides treatment on cardiac chymase activities and cardiomyopathy in diabetic hamsters. Acta Diabetol 47 (Suppl 1): S35-S46l.
16. Takahashi R, Okumura K, Matsui H, Saburi Y, Kamiya H, et al. (2003) Impact of α-tocopherol on cardiac hypertrophy due to energy metabolism disorder: the involvement of 1,2-diacylglycerol. Cardiovasc Res 58: 565-74.
17. Saburi Y, Okumura K, Matsui H, Hayashi K, Kamiya H, et al. (2003) Changes in distinct species of 1,2-diacylglycerol in cardiac hypertrophy due to energy metabolic disorder. Cardiovasc Res 57: 92-100.
18. Belke DD, Lasen TS, Lopaschuk GD, Severson DL, (1999) Glucose and fatty acid metabolism in the isolated working mouse heart. Am J Physiol 277: R1210-R1217.
19. Finck B, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, et al. (2002) The cardiac phenotype induced by PPARα overexpression mimics that cuased by diabetes mellitus. J Clin Invest 109: 121-130.
20. Finck B, Han X, Courtois M, Aimond F, Nerbonne JM, et al. (2003) A critical role for PPARα- mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: Modulation of phenotype by dietary fat content. Proc Natl Acad Sci USA 100: 1226-1231.
21. Proornima IG, Parikh P, Shannon RP, (2006) Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 98: 596-605.
22. Watanabe K, Fujii H, Takahashi T, Kodama M, Aizawa Y, et al. (2000) Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor α associated with age- dependent cardiac toxicity. J Biol Chem 275: 22293-22299.
23. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, et al. (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30: 595-602.
24. Gamble J, Lopaschuk GD, (1994) Glycolysis and glucose oxidation during reperfusion of ischemic hearts from diabetic rats. Biochim Biophys Acta 1225: 191-199.
25. Schaffer JE, (2003) Lipotoxicity: when tissues overeat. Curr Opin Lipidol 14: 281-287.
26. Young ME, Laws FA, Goodwin GW, Taegtmeyer H, (2001) Reactivation of peroxisome proliferator- actated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem 276: 44390-44395.
27. Duncan JG, Fong JL, Medeiros DM, Finck BN, Kelly DP, (2007) Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1 alpha gene regulatory pathway. Circulation 115: 909-917.
28. Yang J, Sambandam N, Ham X, Gross RW, Courtosis M, et al. (2007) CD36 deficiency rescues lipotoxic cardiomyopathy. Circ Res 100: 1208-1217.